Key result
Genotype positive Short QT Syndrome carries no higher malignant arrhythmia risk versus genotype negative patients.
Why the study?
Short QT syndrome affects different types of genes, but data comparing the clinical profile and outcomes across different SQTS types are sparse.
Does the clinical profile and outcome differ between genotype positive and genotype negative Short QT Syndrome patients?
Systematic Review (n=110)
Does the clinical profile and outcome differ between genotype positive and genotype negative Short QT Syndrome patients?
Absolute Event Rate: 13% vs 9%
p-value: p=0.25
Genotype positive and negative Short QT Syndrome patients share similar risks for malignant ventricular arrhythmias, though genotype positive patients are more likely to present with atrial fibrillation.
BACKGROUND: Short QT syndrome (SQTS) is a rare syndrome and affects different types of genes. However, data on differences of clinical profile and outcome of different SQTS types are sparse. METHODS: We conducted a pooled analysis of 110 SQTS patients. Patients have been diagnosed between 2000 and 2017 at our institution (n = 12) and revealed using a literature review (n = 98). 29 studies were identified by analysing systematic data bases (PubMed, Web of Science, Cochrane Libary, Cinahl). RESULTS: 67 patients with genotype positive SQTS origin and 43 patients with genotype negative origin were found. A significant difference is documented between the sex with a higher predominance of male in genotype negative SQTS patients and predominance of females in genotype positive SQTS patients (male 52% versus 84%, female 45% versus 14%; p = 0.0016). No relevant difference of their median age (genotype positive 27 ± 19 versus genotype negative 29 ± 15; p = 0.48) was found. Asymptomatic patients and patients reporting symptoms such as syncope, sudden cardiac death, atrial flutter and ventricular fibrillation documented in both groups were similar except atrial fibrillation (genotype positive 19% versus genotype negative 0%; p = 0.0055). The QTc interval was not significantly different in both groups (genotype positive 315 ± 32 versus genotype negative 320 ± 19; p = 0.30). The treatments (medical treatment and ICD implantation) in both groups were comparable. Electrophysiology studies were not significantly higher documented in patients with genotype positive and negative origin (24% versus 9%; p = 0.075). Events at follow up such as VT, VF, and SCD were not higher presented in patients with genotype positive (13% versus 9%) (p = 0.25). 54% of genotype positive SQTS patients showed SQTS 1 followed by STQS 2 (21%) and SQTS 3 (10%). CONCLUSIONS: The long-term risk of a malignant arrhythmic event is not higher in patients with genotype positive. However, patients with genotype positive present themselves more often with AF with a female predominance. Also, other events at follow up such as syncope, atrial flutter and palpitation were not significantly higher (9% versus 0%; p = 0.079).
No takes yet. Share an insight, caveat, or question.
Raschwitz et al. (2020) conducted a systematic review in Short QT Syndrome (SQTS) (n=110). Genotype positive SQTS vs. Genotype negative SQTS was evaluated on Malignant arrhythmic events at follow-up (VT, VF, and SCD) (p=0.25). Genotype positive Short QT Syndrome patients do not have a significantly higher long-term risk of malignant arrhythmic events compared to genotype negative patients (13% vs 9%, p=0.25).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: